Recursion Pharmaceuticals Inc News - RXRX

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 424B7 - Prospectus [Rule 424(b)(7)]

Form 144 - Report of proposed sale of securities

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which...

Form 3 - Initial statement of beneficial ownership of securities

bwrbad 1 day ago

balding haircut at RXRX

👍️0

Monksdream 1 week ago

RXRX, under $7

👍️0

bwrbad 2 weeks ago

out for now, let CEO work his magic if he has one under his sleeve

👍️0

bwrbad 2 weeks ago

is something wrong with RxRx, it looked promising based on what said to public. but something not right. ground shaken up. - like trouble.
what wrong with the CEO. if this continues that is bad sign for future of the company and the CEO.

RxRx partnership: GOOG NVDA MSFT Roche/Genentech Bayer Bristol Myers Squibb Sanofi Merck ......

👍️0

bwrbad 3 weeks ago

RxRx M&A: Valence –Cyclica - Exscientia
Valence – a leader in generative AI and deep learning models
Cyclica - a deep learning engine that predicts the polypharmacology of small molecules in drug discovery.
Exscientia - AI-driven precision medicine
RXRX - Regenerative AI - TechBio powerhouse
undergoing post merger reorganization, some job cuts
enough cash to fund through 2027
Ark Q3 2024 Stake: $215.9 million
Hedge Fund Investors Q3 2024:: 16
more than ten drugs in trials.

👍️0

bwrbad 3 weeks ago

market up big and RxRx ignored,
if quantum computing which is 7-10 years away getting attention now, then this should be in the rocket heading for stratosphere.

👍️0

TucsonPhil 3 weeks ago

RXRX seeing some promising results in early trials. Proof of concept will solidify belief in the platform.

If cost of trials can be reduced, by less attrition of candidates, then they should see more licensing agreements, and funding, from pharma companies IMO.

👍️ 1

bwrbad 3 weeks ago

Revenue (ttm) 65.18M; Quarterly Revenue Growth (yoy) 147.60%
Total Cash (mrq) 427.65M; Total Debt (mrq) 90.62M
Shares Outstanding 6 388.94M; Float 8 252.42M
clinical trial : REC-994 in Phase 2, REC-2282 in Phase 2/3; few other in phase 1 and 2, all in less than 2 year not 15-18 years (conventional).

% Held by Institutions 1 69.40% Shares Short (Nov 15, 2024) 4 64.57M 25%

👍️ 1

JJ8 3 weeks ago

Rxrx share price Long Tail Up since 06 Dec 2024.

👍️0

paperman 3 weeks ago

Phase 1 news expected tonight at conference.

👍️0

paperman 3 weeks ago

Phase 1 news expected tonight at conference.

👍️0

bwrbad 3 weeks ago

this is one magnificent AI drug discovery platform - be household name like google tesla Microsoft ...

👍️0

JJ8 4 weeks ago

Bought it yesterday at $6.60

Today it's up about 22%.

Same story with 2 other stocks and they all go up today more than 20%!

Whoa! IN CREDIBLE!

👍️0

TucsonPhil 4 weeks ago

Agreed, but there will be wild swings, until they get their footing with clinical trials proving the concept works. Trade it until then, and keep one foot in the door for surprise announcements.

👍️0

bwrbad 4 weeks ago

RxRx going to be top player in future pharma drug discovery

👍️0

TucsonPhil 4 weeks ago

Good company, but MMs playing games this morning. Insider buying? News? Who knows? Missed this runup, but will wait for the dip again.

👍️0

bwrbad 4 weeks ago

GOOG -- RxRx -- NVDA -- RxRx -- MSFT

👍️0

bwrbad 4 weeks ago

agree but better, much bigger scope, on way to become a high flying company of the future
price target 150 in two year

👍️0

uksausage 4 weeks ago

no it is the PLTR of Drug discovery
both rely on NVDA to run fast

👍️0

bwrbad 4 weeks ago

started buying little little- this is NVDA of DRUG DISCOVERY

👍️0

ToucanYoucan 4 weeks ago

$RXRX - That's why I'm planning to steadily accumulate shares - with the hope that one or more of these new treatments materializes.

👍️0

bwrbad 4 weeks ago

high potential if delivers,

👍️0

TucsonPhil 4 weeks ago

Good gains in past week, but looks like it is getting ready to drift lower again.

👍️0

TucsonPhil 4 weeks ago

First patient dosed.

https://ir.recursion.com/news-releases/news-release-details/recursion-announces-first-patient-dosed-phase-12-clinical-study

👍️0

lambchops 1 month ago

Glad to see the uptick! Was beaten down for a while. Too good of stock to be down for long.

LC

RXRX

👍️ 1

ToucanYoucan 1 month ago

$RXRX - Having a huge day here!!

👍️0

ToucanYoucan 1 month ago

$RXRX - Nice move up today! This will take a little time to find its footing pps-wise after the merger...imo

👍️0

TucsonPhil 2 months ago

Many foreign countries supplying pharmaceuticals to U.S. at exorbitant markups.

Will anything be done about that? I do not believe tariffs will help with that problem, since people either pay, whatever the cost, or suffer and die.

👍️0

Monksdream 2 months ago

RXRX 10Q 11/6

👍️0

Monksdream 2 months ago

RXRX under $10

👍️0

Monksdream 2 months ago

abrooklyn 3 months ago

https://x.com/RecursionPharma/status/1841453309342740925

👍️0

TucsonPhil 3 months ago

So many clinical trials in work, but for this to translate to value, they will need to show high efficacy and a much shorter time-to-market, using Recursion platform. The problem may be that Recursion can identify promising candidates quickly, but the slow-moving follow-on processes will still eat up valuable time. The value proposition here is the decrease in attrition, for candidates that fail in early stage trials.

https://ir.recursion.com/news-releases/news-release-details/recursion-gives-guidance-seven-clinical-readouts-within-18

https://www.recursion.com/pipeline

https://www.stockscores.com/charts/charts/?ticker=RXRX

👍️0

lambchops 4 months ago

Yes. Good stock to put on watchlist IMO.
Still reasonably cheap. Check MACD.

LC

RXRX

👍️0

mick 4 months ago

diamond in the ruff

RXRX
Recursion Pharmaceuticals Inc
6.32
0.20 (3.27%)
Volume: 3,082,418
Day Range: 6.055 - 6.32
Last Trade Time: 4:28:47 PM EDT

👍️0

mick 4 months ago

RXRX
Recursion Pharmaceuticals Inc
5.95
-0.22 (-3.57%)
Volume: 4,577,882
Day Range: 5.895 - 6.30
Last Trade Time: 7:58:59 PM EDT

👍️0

lambchops 4 months ago

Yes, I've been adding shares of RXRX this week.

LC

RXRX

👍️0

TucsonPhil 4 months ago

Looks.like a little dilution, but a good buying opportunity, to add some more.

👍️0

lambchops 4 months ago

Judging on the reaction some investors must not have liked it either.Will be a strong company into RXRX.I like buying good companies that have a downdraft. They usually come back strong.
Please note I own shares in this company.

LC

RXRX

👍️0

TucsonPhil 4 months ago

I had not seen that merger announcement. Never came across in my broker news feed.

👍️0

lambchops 4 months ago

Did you see the possible merger news?

LC

RXRX

👍️0

TucsonPhil 4 months ago

Running millions of tests per week, to find promising drug candidates.

What we do not know, is how many candidates have entered clinical trials.

When news pops about RXRX origination of promising cures, this will skyrocket.

Oops, missed this one:

https://ir.recursion.com/news-releases/news-release-details/recursion-announces-phase-2-data-rec-994-first-disease

👍️0

lambchops 4 months ago

Looks ready to move IMO.

LC

RXRX

👍️0

TucsonPhil 4 months ago

Looking for a move into the 9.25-9.50 range within the next few weeks.

👍️0

lambchops 4 months ago

RXRX looks ready for another move upward.

👍️0

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Recursion Pharmaceuticals Inc (RXRX)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

RXRX News

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 424B7 - Prospectus [Rule 424(b)(7)]

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Form 3 - Initial statement of beneficial ownership of securities

RXRX Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Recursion Pharmaceuticals Inc (RXRX) News

Recursion Pharmaceuticals Inc (RXRX)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

RXRX News

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 424B7 - Prospectus [Rule 424(b)(7)]

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Form 3 - Initial statement of beneficial ownership of securities

RXRX Discussion

Your Recent History

Go Ad-Free